Immix Biopharma Investor Presentation Deck
IMX-111: GLUT1 Biomarker-targeted for Colorectal Cancer
iMX-111 is a Tissue-Specific Biologic™ built on our
TME Normalization Technology with proprietary
GLUT1 antibody biomarker targeting facilitating
preferential accumulation in glucose-consuming
cancer cells such as colorectal cancer.
ImmixBio
Proprietary
GLUT-1 scFv
antibody
www.
wwww..
-PEG-PE
=DOX
=CUR
wwwww
www.
¡MX-111
www.
www.
www.
www
wwwww
www.
www
17-23nm diameter
IgG Antibody: 10-15nm diameter
01
¡MX-111's GLUT1 target is
overexpressed on
Colorectal and other
cancers
02
GLUT1 is associated with
poor prognosis in colorectal
cancer
03
100% survival @ 24 days
vs. 0% control survival
in colorectal cancer
xenograft model
Percentage of tumors
with increased GLUT1
expression compared
to non-tumorous tissue
(Adapted from Amann, 2009)
%
Survival
I+II
100
Overexpression of GLUT1 Associated With
Stage 3/4 Colorectal Cancer (Shen, 2011)
Dosing Schedule
¡MX-111
80
60
40
20
0
0 2
III+IV
4
A
6
A
Brain (glia cell)
Esophagus
Colon/rectum
8
Ovarian
Stomach
Bile duct
Lung
A
Endometrium
Breast
Colorectal Cancer Stage
Relative Value of
GLUT1 Expression
in colorectal cancer
PBS - Control
10 12 14 16
A
Healthy
Normal
Colon No/
Light
GLUT1
Staining
HCT-116 CRC Xenograft Model: Survival Curve
18
●●●
IMMIX
S BIOPHARMA
(Adapted from Haber, 1998)
¡MX-111
72%
71%
3
92%
86%
86%
81%
76%
100%
100%
Source: Adapted from Abouzeid, et. al. Anti-cancer activity of anti-GLUT1 antibody targeted polymeric micelles co-loaded with curcumin and doxorubicin (2013 - https://doi.org/10.3109/1061186x.2013.840639); Shen, et al. Overexpression of GLUT1 in colorectal
cancer is independently associated with poor prognosis. Int J Biol Markers. Jul-Sep 2011;26(3):166-72. doi: 10.5301/JBM.2011.8550. Epub 2011 Jul 22. Amman, et al. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009
Dec;13(12):1411-27. doi: 10.1517/14728220903307509; Haber, et al. GLUT1 Glucose Transporter Expression in Colorectal Carcinoma: A Marker for Poor Prognosis. Cancer. 1998 Jul 1;83(1):34-40. doi: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-
cncr5>3.0.co;2-e.
Colorectal
Carcinoma
Heavy
GLUT1
Staining
20 22 24 26 28 30 32 34 36 38 40 42
Days After Initial Treatment (Adapted from Abouzeid et al, 2013)
52View entire presentation